November 22, 2021 -- Regeneron has extended its research agreement with Decibel Therapeutics for the development of gene therapies for hearing loss.
The agreement will be extended through November 2023, and Regeneron will pay Decibel and extension fee of $10 million in the fourth quarter of 2022.
The collaboration was initially launched in 2017. Under the agreement, Decibel is developing three gene therapies that target congenital, monogenic hearing loss with Regeneron. In 2022, Decibel plans to begin a phase I/II clinical trial of DB-OTO, its lead gene therapy candidate, the two firms said.